• Over the past week, uniQure N.V. completed an upsized US$225,000,003 follow-on equity offering of 4,945,055 ordinary shares at US$45.50 each, shortly after reporting initial AMT-260 epilepsy data and confirming FDA support for using three-year AMT-130 results as the basis for an accelerated approval filing in Huntington’s disease.
• An interesting angle is how uniQure is pairing early but encouraging central nervous system gene therapy readouts with an expanded share capital base to fund commercialization readiness and a confirmatory Huntington’s study.
• We will now examine how FDA receptiveness to an accelerated AMT-130 filing could reshape uniQure’s investment narrative around Huntington’s disease.

The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

uniQure Investment Narrative Recap

To own uniQure, you have to believe that AMT‑130 can clear a complex FDA path in Huntington’s disease and become a commercially relevant product, while earlier programs like AMT‑260 add longer term pipeline value. The upsized US$225.0 million equity raise meaningfully extends the company’s cash runway ahead of the planned Q3 2026 AMT‑130 BLA, but also reinforces dilution and the core risk that regulatory timelines or requirements still shift.

The most relevant recent announcement is the FDA’s indication that three year AMT‑130 data could support an accelerated approval filing, with a confirmatory study agreed upfront. This gives clearer regulatory direction around the key Huntington’s catalyst, even as uniQure’s small current revenue base and history of operating losses keep financial execution and future funding needs firmly in focus for shareholders.

Yet even with FDA openness to an accelerated filing, investors should be aware that...

uniQure’s narrative projects $242.2 million in revenue and $46.0 million in earnings by 2029. This requires 137.4% yearly revenue growth and a $254.9 million earnings increase from -$208.9 million today.

Uncover how uniQure's forecasts yield a $52.56 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were assuming revenue of only about US$41.0 million and earnings near US$6.6 million by 2028, and they focus heavily on the risk that regulators could still demand longer, larger AMT‑130 trials, before even factoring in this latest FDA feedback and equity raise.

Explore 5 other fair value estimates on uniQure - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your uniQure research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.